ehealth digital library

Digital library of
the Tanzania
health
community

AtriplaR/anti-TB Combination in TB/HIV Patients. Drug in Focus.

Semvua, H. H. and Kibiki, G. S. (2011) AtriplaR/anti-TB Combination in TB/HIV Patients. Drug in Focus. BMC research notes, 4. p. 511. ISSN 1756-0500

[img]
Preview
PDF
Hadija_H_Semvua.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial.

Download (233kB)

Abstract

Co-administration of anti-tuberculosis and antiretroviral therapy is often inevitable in high-burden countries where tuberculosis is the most common opportunistic infection associated with HIV/AIDS. Concurrent use of rifampicin and several antiretroviral drugs is complicated by pharmacokinetic drug-drug interaction. Pubmed and Google search following the key words tuberculosis, HIV, emtricitabine, tenofovir efavirenz, interaction were used to find relevant information on each drug of the fixed dose combination AtriplaR RESULTS: Information on generic name, trade name, pharmacokinetic parameter, metabolism and the pharmacokinetic interaction with Anti-TB drugs of emtricitabine, tenofovir, and efavirenz was obtained. Fixed dose combination of emtricitabine/tenofovir/efavirenz (ATRIPLAR) which has been approved by Food and Drug Administration shows promising results as far as safety and efficacy is concerned in TB/HIV co-infection patients, hence can be considered effective and safe antiretroviral drug in TB/HIV management for adult and children above 3 years of age.

Item Type: Article
Keywords: Tuberculosis, HIV, Emtricitabine, Tenofovir, Efavirenz, Interaction
Subjects: Tuberculosis > Treatment
Divisions: Kilimanjaro Christian Medical Centre
Depositing User: Mr Joseph Madata
Date Deposited: 28 Aug 2013 09:48
Last Modified: 28 Aug 2013 09:48
URI: http://ihi.eprints.org/id/eprint/1974

Actions (login required)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics